Deadline: 22-Jun-2026
The Quarterly Research Grant Funding Programme by Cure Parkinson’s supports innovative preclinical and clinical research aimed at slowing, stopping, or reversing Parkinson’s disease. It offers funding up to £250,000 for high-impact projects with strong potential to progress to human clinical trials within five years. The programme follows a structured two-stage application and rigorous peer review process to accelerate breakthrough therapies.
The Quarterly Research Grant Funding Programme is designed to accelerate scientific discovery and therapeutic innovation in Parkinson’s disease.
It supports:
- Preclinical research (laboratory-based studies)
- Clinical research (human-focused studies and trials)
- Translational research (bridging lab discoveries to patient treatments)
Core Objective
To fast-track promising research into real-world treatments that can be tested in people living with Parkinson’s disease.
Key Focus Areas and Priorities
1. Preclinical Research
- Laboratory-based studies
- Drug discovery and early testing
- Mechanism-focused research
2. Clinical Research
- Clinical trials and sub-studies
- Patient-centered interventions
- Real-world therapeutic testing
3. Translational Potential
- Projects must aim to:
- Progress toward human clinical trials within 5 years
- Demonstrate clear pathways from research to treatment
4. Funding Scope
- Up to £250,000 GBP for preclinical projects
- Additional support for:
- Clinical trials
- Related sub-studies
5. Compliance and Governance
- Must follow:
- Grant terms and conditions
- UK government regulations (via GOV.UK guidance)
- Trusted Research and national security frameworks
What Makes This Programme Unique?
Translational Focus
Unlike basic research grants, this programme prioritizes practical outcomes—moving discoveries from the lab to clinical use.
Global Accessibility
- Open to international applicants
- Encourages global collaboration
Inclusive Research Review
- Includes expert peer reviewers
- May involve people with lived experience of Parkinson’s disease in clinical study evaluation
Who is Eligible?
Eligible Applicants
- Academic institutions (universities, research centers)
- Commercial organizations (biotech, pharma companies)
- International applicants
Key Requirements
- Proven research expertise in Parkinson’s or related fields
- Strong scientific and methodological design
- Demonstrated translational potential
Special Conditions for Commercial Applicants
- Must justify costs carefully
- Costs should align with academic-level benchmarks
Why This Funding Matters
Accelerates Treatment Development
- Speeds up the transition from discovery to clinical trials
Supports High-Impact Innovation
- Funds research with potential to change disease outcomes
Encourages Global Collaboration
- Brings together academic and commercial expertise worldwide
Improves Patient Outcomes
- Focuses on therapies that can:
- Slow progression
- Stop disease advancement
- Potentially reverse symptoms
Funding Details
- Maximum Funding: £250,000 GBP (for preclinical research)
- Project Timeline Expectation: Progress toward clinical trials within 5 years
- Geographic Scope: Global
- Funding Frequency: Quarterly calls
How the Application Process Works
The application process follows a two-stage structure:
Stage 1: Initial Submission
- Submit a brief proposal
- Outline:
- Research idea
- Objectives
- Expected impact
Stage 2: Full Application (By Invitation Only)
Shortlisted applicants must submit:
- Detailed study design
- Full methodology
- Budget justification
- Institutional approvals
- Signed letter of support
Peer Review Process
- Reviewed by at least two independent experts
- Additional reviewers for complex proposals
- Clinical proposals may include:
- Input from individuals with Parkinson’s experience
Final Decision
The review committee may:
- Approve funding
- Request revisions
- Reject the proposal
Applicants may also defer submission to a future round if needed.
Step-by-Step: How to Apply
Step 1: Check Eligibility
- Confirm institutional and research eligibility
Step 2: Prepare Stage 1 Proposal
- Focus on innovation and translational potential
Step 3: Submit Application
- Follow official submission guidelines
Step 4: Respond to Feedback
- Incorporate review committee suggestions
Step 5: Submit Stage 2 Application
- Provide full technical and financial details
Step 6: Undergo Peer Review
- Address reviewer comments if required
Step 7: Final Approval
- Await funding decision
Common Mistakes to Avoid
- Weak translational pathway (no clear route to clinical trials)
- Overly theoretical research with no practical application
- Poor budget justification
- Compliance with regulatory or ethical standards
- Incomplete documentation
Pro Tips for Success
- Clearly define clinical impact
- Show feasibility within 5 years
- Align proposal with programme priorities
- Include strong supporting data
Frequently Asked Questions (FAQ)
1. What is the main goal of this programme?
To fund research that can lead to effective treatments for Parkinson’s disease within a short timeframe.
2. Who can apply?
Academic institutions and commercial organizations worldwide.
3. What is the maximum funding available?
Up to £250,000 for preclinical research projects.
4. What types of research are supported?
Both preclinical (lab-based) and clinical (human-focused) research.
5. How does the application process work?
It involves a two-stage process: initial proposal and full application with peer review.
6. Are international applicants eligible?
Yes, the programme is open globally.
7. What is meant by translational research?
Research that moves scientific discoveries from the lab into clinical applications.
Conclusion
The Quarterly Research Grant Funding Programme by Cure Parkinson’s is a high-impact funding opportunity for researchers committed to advancing Parkinson’s disease treatment.
With its strong emphasis on translational science, global collaboration, and clinical impact, the programme plays a critical role in accelerating the journey from discovery to real-world therapies.
For more information, visit Cure Parkinson’s.
